# Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

> **NCT01532648** · PHASE3 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 510 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Budesonide MMX®
- **DRUG:** Placebo
- **DRUG:** 5-ASA

## Key facts

- **NCT ID:** NCT01532648
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-27
- **Primary completion:** 2013-10-02
- **Final completion:** 2013-10-02
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532648, "Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01532648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*